Bristol Myers: accelerated approval in colorectal cancer
This approval is based on the results of the phase 1/2 KRYSTAL-1 study, in which this combination showed an objective response rate of 34% in pre-treated patients with this type of cancer.
This is the second FDA approval for Krazati - reinforcing its potential in all tumor types. Continuation of this indication may depend on verification and description of clinical benefit in a confirmatory trial.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction